These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 19758845)

  • 1. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.
    Ananthan S; Faaleolea ER; Goldman RC; Hobrath JV; Kwong CD; Laughon BE; Maddry JA; Mehta A; Rasmussen L; Reynolds RC; Secrist JA; Shindo N; Showe DN; Sosa MI; Suling WJ; White EL
    Tuberculosis (Edinb); 2009 Sep; 89(5):334-53. PubMed ID: 19758845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antituberculosis activity of the molecular libraries screening center network library.
    Maddry JA; Ananthan S; Goldman RC; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Reynolds RC; Secrist JA; Sosa MI; White EL; Zhang W
    Tuberculosis (Edinb); 2009 Sep; 89(5):354-63. PubMed ID: 19783214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-tuberculosis agents amongst known drugs.
    Lougheed KE; Taylor DL; Osborne SA; Bryans JS; Buxton RS
    Tuberculosis (Edinb); 2009 Sep; 89(5):364-70. PubMed ID: 19699151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.
    Reynolds RC; Ananthan S; Faaleolea E; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Sosa MI; Thammasuvimol E; White EL; Zhang W; Secrist JA
    Tuberculosis (Edinb); 2012 Jan; 92(1):72-83. PubMed ID: 21708485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
    Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
    Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium tuberculosis High-Throughput Screening.
    White EL; Tower NA; Rasmussen L
    Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility.
    Goldman RC; Laughon BE; Reynolds RC; Secrist JA; Maddry JA; Guié MA; Poffenberger AC; Kwong CA; Ananthan S
    Infect Disord Drug Targets; 2007 Jun; 7(2):92-104. PubMed ID: 17970221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
    Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA
    Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem.
    Goldman RC
    Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and validation of new antitubercular compounds as potential drug leads and probes.
    Goldman RC; Laughon BE
    Tuberculosis (Edinb); 2009 Sep; 89(5):331-3. PubMed ID: 19716767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 13. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.
    Ballell L; Bates RH; Young RJ; Alvarez-Gomez D; Alvarez-Ruiz E; Barroso V; Blanco D; Crespo B; Escribano J; González R; Lozano S; Huss S; Santos-Villarejo A; Martín-Plaza JJ; Mendoza A; Rebollo-Lopez MJ; Remuiñan-Blanco M; Lavandera JL; Pérez-Herran E; Gamo-Benito FJ; García-Bustos JF; Barros D; Castro JP; Cammack N
    ChemMedChem; 2013 Feb; 8(2):313-21. PubMed ID: 23307663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel synthesis of chiral pentaamines and pyrrolidine containing bis-heterocyclic libraries. Multiple scaffolds with multiple building blocks: a double diversity for the identification of new antitubercular compounds.
    Nefzi A; Appel J; Arutyunyan S; Houghten RA
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5169-75. PubMed ID: 19632841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis.
    Makane VB; Krishna VS; Krishna EV; Shukla M; Mahizhaveni B; Misra S; Chopra S; Sriram D; Azger Dusthackeer VN; Rode HB
    Future Med Chem; 2019 Mar; 11(6):499-510. PubMed ID: 30892944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.